Redox proteomics in study of kidney-associated hypertension: New insights to old diseases

Antioxidants and Redox Signaling

Volumn 17, Issue 11, 2012, Pages 1560-1570

  Sheehan, David ^a   Rainville, Louis Charles ^a   Tyther, Raymond ^a   McDonagh, Brian ^b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ALPHA TOCOPHEROL; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANGIOTENSINOGEN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CATALASE; CYSTEINE; DIPEPTIDYL CARBOXYPEPTIDASE; FIBROBLAST GROWTH FACTOR 23; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTAREDOXIN; GLUTATHIONE; HYDROGEN PEROXIDE; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 6; METHIONINE; OXYGEN; PEROXIREDOXIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RENIN; SUPEROXIDE DISMUTASE; THIOREDOXIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANTIOXIDANT ACTIVITY; BLOOD ANALYSIS; CHRONIC KIDNEY DISEASE; CYTOKINE PRODUCTION; EXPERIMENTAL MODEL; HEYMANN NEPHRITIS; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; IMMUNE COMPLEX NEPHRITIS; ISOBARIC TAG FOR RELATIVE AND ABSOLUTE QUANTIFICATION; ISOELECTRIC FOCUSING; ISOTOPE CODED AFFINITY TAG; ISOTOPE LABELING; JUXTAGLOMERULAR APPARATUS; KIDNEY BLOOD FLOW; KIDNEY CORTEX; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY MEDULLA; KIDNEY PARENCHYMA; KIDNEY TUBULE ACIDOSIS; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MONITORING; NEPHRITIS; NITROSATIVE STRESS; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN PROCESSING; PROTEOMICS; RENAL DIABETES; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REPERFUSION INJURY; REVIEW; SELECTIVE REACTION MONITORING; SEPSIS; STABLE ISOTOPE LABELING OF AMINO ACID IN CELL CULTURE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TISSUE OXYGENATION; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; TWO DIMENSIONAL ELECTROPHORESIS; URINALYSIS;

BIOLOGICAL MARKERS; BLOOD PROTEINS; HUMANS; HYPERTENSION, RENAL; KIDNEY DISEASES; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN CARBONYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOME;

ANIMALIA;

EID: 84866860109     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.4705     Document Type: Review

References (90)

1. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, and Nieto MA. Epithelial-mesenchymal transitions: The importance of changing cell state in development and disease. J Clin Invest 119: 1438-1449, 2009.
2. Albalat A, Mischak H, and Mullen W. Clinical application of urinary proteomics/peptidomics. Expert Rev Proteomics 8: 615-629, 2011.
3. Alhaider AA, Korashy HM, Sayed-Ahmed MM, Mobark M, Kfoury H, and Mansour MA. Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through modulation of oxidative stress genes expression. Chem Biol Interact 192, 233-242, 2011.
4. Barati MT, Merchant ML, Kain AB, Jevans AW, McLeish KR, and Klein JB. Proteomic analysis defines altered cellular redox pathways and advanced glycation end product metabolism in glomeruli of db/db diabetic mice. Am J Physiol Renal Physiol 293: F1157-F1165, 2007 (Pubitemid 47583949)
5. Benigni A, Cassis P, and Remuzzi G. Angotensin II revisited: New roles in inflammation, immunology and aging. EMBO Mol Med 2: 247-257, 2010.
6. Blutke A, Block C, Berendt F, Herbach N, Kemter E, Amann K, Frohlich T, Arnold GJ, and Wanke R. Differential glomerular proteome analysis of two murine nephropathy models at onset of albuminuria. Proteomics Clin App 5: 375-381, 2011.
7. Braun MC, Li L, Ke BZ, Dubinsky WP, Pickering MC, and Chang YJ. Proteomic profiling of urinary protein excretion in the factor H-deficient mouse. Am J Nephrol 26: 127-135, 2006. (Pubitemid 43882396)
8. Bruschi M, Candiano G, Della Ciana L, Petretto A, Santucci L, Prunotto M, Camilla R, Coppo R, and Ghiggeri GM. Analysis of the oxido-redox status of plasma proteins: Technology advances for clinical proteomics. J Chromatogr B Analyt Technol Biomed Life Sci 879: 1338-1344, 2011.
9. Butte AJ, Sigdel TK, Wadia PP, Miklos DB, and Sarwal MM. Protein microarrays discover angiotensinogen and PRKRIP1 as novel targets for autoantibodies in chronic renal disease. Mol Cell Proteomics 10: M110.000497, 2011.
10. Charonis A, Luider T, Baumann M, and Schanstra JP. Is the time ripe for kidney tissue proteomics? Proteomics Clin App 5: 215-221, 2011.
11. Chen YX, Li Y, Wang WM, Zhang W, Chen XN, Xie YY, Lu J, Huang QH, and Chen N. Phosphoproteomic study of human tubular epithelial cell in response to transforming growth factor-beta-1 induced epithelial-to-mesenchymal transition. Am J Nephrol 31: 24-35, 2010.
12. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, van Lente F, and Levey AS. Prevalence of chronic kidney disease in the United States. J Am Med Assoc 298: 2038-2047, 2007. (Pubitemid 350074801)
13. Costenoble R, Picotti P, Reiter L, Stallmach R, Heinemann M, Sauer U, Stallmach R, Heinemann M, Sauer U, and Aebersold R. Comprehensive quantitative analysis of central carbon and amino-acid metabolism in Saccharomyces cerevisiae under multiple conditions by targeted proteomics. Mol Syst Biol 7: 464, 2011.
14. Curthoys NP, Taylor L, Hoffert JD, and Knepper MA. Proteomic analysis of the adaptive response of rat renal proximal tubules to metabolic acidosis. Am J Physiol Renal Physiol 292: F140-F147, 2007. (Pubitemid 46105253)
15. Dounousi E, Papavasiliou E, Makedou A, Loannou K, Katopodis KP, Tselepis A, Siamopoulos KC, and Tsakiris D. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 48: 752-760, 2006. (Pubitemid 44740054)
16. Eaton P, Jones ME, McGregor E, Dunn MJ, Leeds N, Byers HL, Leung KY, Ward MA, Pratt JR, and Shattock MJ. Reversible cysteine-targeted oxidation of proteins during renal oxidative stress. J Am Soc Nephrol 14: S290-S296, 2003. (Pubitemid 36903942)
17. Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, and Hoy WE. Biomarkers in chronic kidney disease: A review. Kidney Int 80: 806-821, 2011.
18. Garcia-Santamarina S, Boronat S, Espadas G, Ayte J, Molina H, and Hidalgo E. The oxidized thiol proteome in fission yeast-optimization of an ICAT-based method to identify H2O2-oxidized proteins. J Proteomics 74: 2476-2486, 2011.
19. Geiszt M and Leto TL. The Nox family of NAD(P)H oxidases: Host defense and beyond. J Biol Chem 279: 51715-51718, 2004. (Pubitemid 39656535)
20. Go AS, Chertow GM, Fan D, McCulloch CE, and Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. N Engl J Med 351: 1296-1305, 2004.
21. Godin N, Liu F, Lau GJ, Brezniceanu M-L, Chenier I, Filep JG, Ingelfinger JR, Zhang S-L, and Chan JSD. Catalase overexpression prevents hypertension and tubular apoptosis in angiotensinogen transgenic mice. Kidney Int 77: 1086-1097, 2010.
22. Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody En, Carter J, Dalby AB, Eaton BE, Fitzwater T, Flather D, Forbes A, Foreman T, Fowler C, Gawande B, Goss M, Gunn M, Gupta S, Halladay D, Heil J, Heilig J, Hicke B, Husar G, Janjic J, Jarvis T, Jennings S, Katilius E, Keeney TR, Kim N, Koch TH, Kraemer S, Kroiss L, Le N, Levine D, Lindsey W, Lollo B, Mayfield W, Mehan M, Mehler R, Nelson SK, Nelson M, Nieuwlandt D, Nikrad M, Ochsner U, Ostroff RM, Otis M, Parker T, Pietrasiewicz S, Resnicow DI, Rohloff J, Sanders G, Sattin S, Schneider D, Singer B, Stanton M, Sterkel A, Stewart A, Stratford S, Vaught JD, Vrkljan M, Walker JJ, Watroba M, Waugh S, Weiss A, Wilcox SK, Wolfson A, Wolk SK, Zhang C, and Zichi D. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 5: e15004, 2010.
23. Hewitson TD. Renal tubulointerstitial fibrosis: Common but never simple. Am J Physiol Renal Physiol 296: F1239-F1244, 2009.
24. Holly MK, Dear JW, Hu X, Schechter AN, Gladwin MT, Hewitt SM, Yuen PST, and Star RA. Biomarker and drugtarget discovery using proteomics in a new rat model of sepsis-induced acute renal failure. Kidney Int 70: 496-506, 2006. (Pubitemid 44141576)
25. Hsu HH, Hoffmann S, di Marco GS, Endlich N, Peter-Katalinic J, Weide T, and Pavenstadt H. Downregulation of the antioxidant protein peroxiredoxin 2 contributes to angiotensin II-mediated podocyte apoptosis. Kidney Int 80: 959-969, 2011.
26. Jain S, De Petris L, Hoshi M, Akilesh S, Chatterjee R, and Liapis H. Expression profiles of podocytes exposed to high glucose reveal new insights into early diabetic glomerulopathy. Lab Invest 91: 488-498, 2010.
27. Jia L, Zhang L, Shao C, Song E, Sun W, and Gao Y. An attempt to understand kidney's protein handling function by comparing plasma and urine proteomes. PLoS One 4: e5146, 2009.
28. Kamijo K, Nabetani T, Tsugita A, Xu B, Zhang Y, Yaoita E, Osawa T, and Yamamoto T. In-depth proteomic profiling of the normal human kidney glomerulus using two-dimensional protein pre-fractionation in combination with liquid chromatography-tandem mass spectrometry. J Proteome Res 6: 3680-3690, 2007. (Pubitemid 47522757)
29. Kanazawa I, Yamamoto M, Yamagichi T, and Sugimoto T. Effects of metformin and piolitazone on serum pentosidine levels in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 119, 362-365, 2011.
30. Kartha G K, Moshal K S, Sen U, Joshua I G, Tyagi N, Steed MM, and Tyagi SC. Renal mitochondrial damage and protein modification in type-2 diabetes. Acta Diabetol 45: 75-81, 2008.
31. Kim H-J, Cho E-H, Yoo J-H, Kim P-K, Shin J-S, Kim M-R, and Kim C-W. Proteome analysis of serum from type 2 diabetics with nephropathy. J Proteome Res 6: 735-743, 2007. (Pubitemid 46340176)
32. Klein J, Kavvadas P, Prakoura N, Karagianni F, Schanstra JP, Bascands JL, and Charonis A. Renal fibrosis: Insight from proteomics in animal models and human disease. Proteomics 11: 805-815, 2011.
33. Koitabashi K, Okamoto K, Arirto M, Sato T, Nagai K, Kurokawa MS, Suematsu N, Yasuda T, Kimura K, and Kato T. Micro-sieving: Isolation of whole glomeruli from a single renal needle biopsy sample. Nephron Clin Pract 117: C225-C229, 2011.
34. Kriz W, Kaissling B, and Le Hir M. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: Fact or fantasy? J Clin Invest 121: 468-474, 2011.
35. Lamoureux F, Mestre E, Essig M, Sauvage FL, Marquet P, and Gastinel LN. Quantitative proteomic analysis of cyclosporine-induced toxicity in a human kidney cell line and comparison with tacrolimus. J Proteomics 75: 677-694, 2011.
36. Levitsky J, Salomon DR, Abecassis M, Langfelder P, Horvath S, Friedewald J, Wang E, Kurian SM, Mondala T, Gil S, McDade R, Ballard K, and Gallon L. Clinical and plasma proteomic markers correlating with chronic kidney disease after liver transplantation. Am J Transplant 11: 1972-1978, 2011.
37. Li YQ, Ji H, Zhang YH, Shi WB, Meng ZK, Chen XY, Du GT, and Tian J. WB1106, a novel nitric oxide-releasing derivative of telmisartan, inhibits hypertension and improves glucose metabolism in rats. Eur J Pharmacol 577: 100-108, 2007. (Pubitemid 47632515)
38. Liu YH. Renal fibrosis: New insights into the pathogenesis and therapeutics. Kidney Int 69: 213-217, 2006.
39. Luczak M, Formanowicz D, Pawliczak E, Wanic-Kossowska M, Wykretowicz A, and Figlerowicz M. Chronic kidney disease-related atherosclerosis-Proteomic studies of blood plasma. Proteome Sci 9: 25, 2011.
40. Madian AG and Regnier FE. Profiling carbonylated proteins in human plasma. J Proteome Res 9: 1330-1343, 2010.
41. Magistroni R, Cantu M, Ligabue G, Masellis M, Spisni E, Furci L, Lupo V, Genovese F, Cavazzini F, and Albertazzi A. Interstitial fluid obtained from kidney biopsy as a new source of renal biomarkers. J Nephrol 24: 329-337, 2011.
42. Mathivanan S and Simpson RJ. ExoCarta: A compendium of exosomal proteins and RNA. Proteomics 9: 4997-5000, 2009.
43. Matsuyama Y, Terawaki H, Terada T, and Era S. Albumin thiol oxidation and serum carbonyl formation are progressively enhanced with advancing stages of chronic kidney disease. Exp Nephrol 13: 308-315, 2009.
44. Mischak H, Kolch W, Aivalotis M, Bouyssie D, Court M, Dihazi H, Dihazi GH, Franke J, Garin J, de Peredo AG, Iphofer A, Jansch L, Lacroix C, Makridakis M, Masselon C, Metzger J, Monsarrat B, Mrug M, Norling M, Novak J, Pich A, Pitta A, Bongcam-Rudloff E, Siwi J, Suzuki H, Thomgboonkerd V, Wang LS, Zoidakis J, Zurbig P, Schanstra JP, and Vlahou A. Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin App 4: 464-478, 2010.
45. Mitrogianni Z, Barbouti A, Galaris D, and Siamopoulos K C. Tyrosine nitration in plasma proteins from patients undergoing hemodialysis. Am J Kidney Dis 44: 286-292, 2004. (Pubitemid 38962557)
46. Mullen W, Delles C, and Mischak H. Urinary proteomics in the assessment of chronic kidney disease. Curr Opin Nephrol Hypertens 20: 654-661, 2011.
47. Nabity MB, Lees GE, Dangott LJ, Cianciolo R, Suchodolski JS, and Steiner JM. Proteomic analysis of urine from male dogs during early stages of tubulointerstitial injury in a canine model of progressive glomerular disease. Vet Clin Pathol 40: 222-236, 2011.
48. Nagaraj N and Mann M. Quantitative analysis of the intraand inter-individual variability of the normal urinary proteome. J Proteome Res 10: 637-645, 2011.
49. Navarro-Gonzalez JF, Mora-Fernandez C., De Fuentes MM, and Garcia-Perez, J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 7: 327-340, 2011.
50. Ngai HHY, Sit WH, Jiang PP, Thongbookerd V, and Wan JMF. Markedly increased urinary prehaptoglobin and haptoglobin in passive Heymann nephritis: A differential proteomic approach. J Proteome Res 6: 3313-3321, 2007.
51. Nistala R, Whaley-Connell A, and Sowers JR. Redox control of renal function and hypertension. Antioxid Redox Signal 10: 2047-2089, 2008.
52. Nistala R, Wei Y, Sowers JR, and Whaley-Connell A. Reninangiotensin- aldosterone system-mediated redox effects in chronic kidney disease. Transl Res 153: 102-113, 2009.
53. Niwa T. Biomarker discovery for kidney diseases by mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 870: 148-153, 2008. (Pubitemid 351992935)
54. Okamoto K and Aoki K. Development of a strain of spontaneously hypertensive rats. Jpn Circ J 27: 282-293, 1963.
55. Pallone TL. Is oxidative stress differentially regulated in the renal cortex and medulla? Nat Clin Pract Nephrol 2: 118-199, 2006.
56. Pesic I, Stefanovic V, Muller GA, Muller CA, Cukuranovic R, Jahn O, Bojanic V, Koziolek M, and Dihazi H. Identification and validation of six proteins as marker for endemic nephropathy. J Proteomics 74: 1994-2007, 2011.
57. Piroddi M, Palmese A, Pilolli F, Amoresano A, Pucci P, Ronco C, and Galli F. Plasma nitroproteome of kidney disease patients. Amino Acids 40: 653-667, 2011.
58. Prunotto M, Carnavelli ML, Candiano G, Murtas G, Bruschi M, Corradini E, Trivelli A, Magnasco A, Petretto A, Santucci L, Mattei S, Gatti R, Scolari F, Kador P, Allegri L, and Ghiggeri GM. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 21: 507-519, 2010.
59. Prunotto M, Ghiggeri GM, Candiano G, Lescuver P, Hochstrasser D, and Moll S. Urinary proteomics and drug discovery in chronic kidney disease: A new perspective. J Proteome Res 10: 126-132, 2011.
60. Rodrigo R, Gonzalez J, and Paoletto F. The role of oxidative stress in the pathophysiology of hypertension. Hypertens Res 34: 431-440, 2011.
61. Rosca MG, Mustata TG, Kinter MT, Ozdemir AM, Kem TS, Szweda LI, Brownlee M, Monnier VM and Weiss MF. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol 289: F420-F430, 2005. (Pubitemid 41003672)
62. Schiffer E, Liabeuf S, Lacroix C, Temmar M, Renard C, Monsarrat B, Choukroun G, Lemke HD, Vanholder R, Mischak H, and Massy ZA. Markers of vascular disease in plasma from patients with chronic kidney disease identified by proteomic analysis. J Hypertens 29: 783-790, 2011.
63. Selmici L. Advanced oxidation protein products (AOPP): Novel uremic toxins, or components of the non-enzymatic antioxidant system of the plasma proteome? Free Radic Res 45: 1115-1123, 2011.
64. Smith MPW, Banks RE, Wood SL, Lewington AJP and Selby PJ. Application of proteomic analysis to the study of renal diseases. Nat Rev Nephrol 5: 701-712, 2009.
65. Son D, Kojima I, Inagi R, Matsumoto M, Fujita T and Nangaku M. Chronic hypoxia aggravates renal injury via suppression of Cu/Zn-SOD: A proteomic analysis. Am J Physiol Renal Physiol 294: F62-F72, 2008.
66. Spasovski G, Ortiz A, Vanholder R and El Nahas M. Proteomics in chronic kidney disease: The issues clinical nephrologists need an answer for. Proteomics Clin App 5: 233-240, 2011.
67. Sui WG, Huang LL, Dai Y, Chen JJ, Yan QA and Huang H. Proteomic profiling of renal allograft rejection in serum using magnetic bead-based sample fractionation and MALDI-TOF MS. Clin Exp Med 10: 259-268, 2010.
68. Swaminathan S and Shah SV. Novel approaches toward oxidative stress for the treatment of chronic kidney disease. Curr Opin Nephrol Hypertens 17, 143-148, 2008. (Pubitemid 351253038)
69. Thongboonkerd V and Malasit P. Renal and urinary proteomics: Current applications and challenges. Proteomics 5: 1033-1042, 2005. (Pubitemid 40469033)
70. Thongboonkerd V, Chutipongtanate S, Kanlaya R, Songtawee N, Sinchaikul S, Parichatikanond P, Chen ST, and Malasit P. Proteomic identification of alterations in metabolic enzymes and signalling proteins in hypokalemic nephropathy. Proteomics 6: 2273-2285, 2006.
71. Tobili JE, Cao G, Giani JF, Angerosa M, Dominici FP, and Gonzalez-Cadavid NF. Antifibrotic effects of pioglitazone at low doses on the diabetic rat kidney are associated with the improvement of markers of cell turnover, tubular and endothelial integrity, and angiogenesis. Kidney Blood Press Res 34, 20-33, 2011.
72. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, and Garg AX. Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 17: 2034-2047, 2006. (Pubitemid 44036188)
73. Tyther R, Ahmeda A, Johns E, and Sheehan D. Proteomic identification of tyrosine nitration targets in kidney of spontaneously hypertensive rats. Proteomics 7: 4555-4564, 2007.
74. Tyther R, Ahmeda A, Johns E, and Sheehan D. Protein carbonylation in kidney medulla of the spontaneously hypertensive rat. Proteomics Clin App 3: 338-346, 2009.
75. Tyther R, Ahmeda A, Johns E, McDonagh B, and Sheehan D. Proteomic profiling of perturbed protein sulfenation in renal medulla of the spontaneously hypertensive rat. J Proteome Res 9: 2678-2687, 2010.
76. Tyther R, McDonagh B, and Sheehan D. Proteomics in investigation of protein nitration in kidney disease: Technical challenges and perspectives from the spontaneously hypertensive rat. Mass Spectrom Rev 30: 121-141, 2011.
77. Unlu M, Morgan ME, and Minden JS. Difference gel electrophoresis: A single gel method for detecting changes in protein extracts. Electrophoresis 18: 2071-2077, 1997. (Pubitemid 27501267)
78. Vaccaro F, Mule G, Cottone S, SoreSi M, Giannatrapani, L, Vadal A, Sparacino V, Calabrese S, Picone FP, Montalto G, and Cerasola G. Circulating levels of adhesion molecules in chronic kidney disease correlate with the stage of renal disease and with c-reactive protein. Arch Med Res 38: 534-538, 2007. (Pubitemid 46873808)
79. van Balkom BWM, Pisitkun T, Verhaar MC, and Knepper MA. Exosomes and the kidney: Prospects for diagnosis and therapy of renal diseases. Kidney Int 80: 1138-1145, 2011.
80. Veenstra TD. Where are all the biomarkers? Expert Rev Proteomics 8: 681-683, 2011.
81. Wang Y, Chen, Y, Zhang Y, Wu SZ, Ma SC, Hu SQ, Zhang L, Shao C, Li MX, and Gao YH. Differential conA-enriched urinary proteome in rat experimental glomerular disease. Biochem Biophys Res Commun 371: 385-390, 2008.
82. Winterbourn CC. Reconciling the chemistry and biology of reactive oxygen species. Nat Chem Biol 4: 278-286, 2008. (Pubitemid 351550893)
83. Wolf G. Role of reactive oxygen species in angiotensin IImediated renal growth, differentiation, and apoptosis. Antioxid Redox Signal 7: 1337-1345, 2006.
84. Wu T, Xie C, Bhaskarabhatla M, Yan M, Leone A, Chen SS, Zhou XJ, Putteman C, and Mohan C. Excreted urinary mediators in an animal model of experimental immune nephritis with potential pathogenic significance. Arthritis Rheum 56: 949-959, 2007. (Pubitemid 46399442)
85. Wuhl E and Schaefer F. Managing kidney disease with blood-pressure control. Nat Rev Nephrol 7: 434-444, 2011.
86. Xu BJ, Shyr Y, Liang XB, Ma LJ, Donnert EM, Roberts JD, Zhang XQ, Kon V, Brown NJ, Caprioli RM, and Fogo AB. Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. J Am Soc Nephrol 16: 2967-2975, 2005. (Pubitemid 44743494)
87. Xu BJ. Combining laser capture microdissection and proteomics: Methodologies and clinical applications. Proteomics Clin App 4: 116-123, 2010.
88. Yoshida Y, Miyazaki K, Sato M, Okuisumi S, Kenmochi A, Kamijo K, Nabetani T, Tsugita A, Xu B, Zhang Y, Yaoita E, Osawa T, and Yamamoto T. Two-dimensional electrophoretic profiling of normal human kidney glomerulus proteome and construction of an extensible markup lan-guage (XML)-based database. Proteomics 5: 1083-1096, 2005. (Pubitemid 40469037)
89. Zhang Y, Yoshida Y, Xu B, Magdeldin S, Fujinaka H, Liu Z, Miyamoto M, Yaoita E, and Yamamoto T. Comparison of human glomerulus proteomic profiles obtained from low quantities of samples by a different mass spectrometry with the comprehensive database. Proteome Sci 9: 47, 2011.
90. Zinellu A, Loriga G, Scanu B, Pisanu E, Sanna M, Deiana L, Satta AE, and Carru C. Increased low-density lipoprotein Shomocysteinylation in chronic kidney disease. Am J Nephrol 32: 242-248, 2010.